News and Events

Xeglyze FDA Approval

3/08/2020 | Press Releases

Hatchtech's commercialisation partner, Dr Reddy's, has achieved FDA approal for Xeglyze.

Press Release

Commercialisation Deal and NDA Filed

14/09/2015 | Press Releases

Hatchtech, an Australian pharmaceutical company developing an innovative prescription head lice product, today announced the signing of a commercialisation agreement with integrated pharmaceutical company Dr. Reddy’s Laboratories (NYSE: RDY) for the rights of Xeglyze™ Lotion in key territories.

Hatchtech also announced it will be filing its New Drug Application for Xeglyze™ with the US Food and Drug Administration (FDA) today.

Media Release_Hatchtech deal_20150914_FINAL.pdf

Hatchtech Announces Successful Phase 3 Results

2/09/2014 | Press Releases

2nd September 2014 Melbourne, Australia

Specialty pharmaceutical company Hatchtech Pty Ltd today announced successful completion of its two pivotal Phase 3 clinical studies evaluating Xeglyze Lotion (formerly DeOvo Lotion) as a potential treatment for head lice infestation.

Hatchtech Completes $12.6m Capital Raise, Secures Funds for Phase III and NDA Submission

31/10/2013 | Press Releases

Hatchtech today announced the completion of a $12.6m capital raise to fund the Phase III clinical trial and NDA submission.  The company also announced several changes to the composition of its Board.

Download PDF